These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23606319)

  • 1. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
    de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
    J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
    Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
    PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
    Conrad C; Miller CR; Ji Y; Gomez-Manzano C; Bharara S; McMurray JS; Lang FF; Wong F; Sawaya R; Yung WK; Fueyo J
    Cancer Gene Ther; 2005 Mar; 12(3):284-94. PubMed ID: 15650766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.
    Balvers RK; Belcaid Z; van den Hengel SK; Kloezeman J; de Vrij J; Wakimoto H; Hoeben RC; Debets R; Leenstra S; Dirven C; Lamfers ML
    Viruses; 2014 Aug; 6(8):3080-96. PubMed ID: 25118638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
    Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
    Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
    Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
    Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.
    Martinez-Velez N; Xipell E; Jauregui P; Zalacain M; Marrodan L; Zandueta C; Vera B; Urquiza L; Sierrasesúmaga L; Julián MS; Toledo G; Fueyo J; Gomez-Manzano C; Torre W; Lecanda F; Patiño-García A; Alonso MM
    J Bone Miner Res; 2014 Oct; 29(10):2287-96. PubMed ID: 24737304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.
    Berghauser Pont LM; Balvers RK; Kloezeman JJ; Nowicki MO; van den Bossche W; Kremer A; Wakimoto H; van den Hoogen BG; Leenstra S; Dirven CM; Chiocca EA; Lawler SE; Lamfers ML
    Gene Ther; 2015 Dec; 22(12):947-59. PubMed ID: 26196249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
    Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
    J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
    Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.
    Fueyo J; Gomez-Manzano C; Alemany R; Lee PS; McDonnell TJ; Mitlianga P; Shi YX; Levin VA; Yung WK; Kyritsis AP
    Oncogene; 2000 Jan; 19(1):2-12. PubMed ID: 10644974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
    Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
    Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
    Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
    White MC; Frampton AR
    Cancer Gene Ther; 2013 Feb; 20(2):88-93. PubMed ID: 23306611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8
    Kleijn A; van den Bossche W; Haefner ES; Belcaid Z; Burghoorn-Maas C; Kloezeman JJ; Pas SD; Leenstra S; Debets R; de Vrij J; Dirven CMF; Lamfers MLM
    Mol Ther Oncolytics; 2017 Jun; 5():11-19. PubMed ID: 28480325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
    Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
    PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.